Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
This content is intended for licensed prescribers and healthcare professionals
Backing by clinical trials
Dies deutet auf eine breite therapeutische Sicherheitsspanne im Tiermodell hin
Both drugs are injectable antibodies that block the function of proprotein convertase subtilisin/kexin type 9, PCSK9
2.1 ALL and AML cells resistant to chemotherapy and increase glycolysis Most of the studies in cell lines and primary samples derived from myeloid and lymphoid leukemias demonstrate a relationship between the increase in the glycolytic pathway and resistance to different types of drugs, such as anthracyclines (daunorubicin, -DNR-, doxorubicin, -DOX-, and idarubicin, -IDA-), some glucocorticoids such as prednisolone, and tyrosine kinase inhibitors (TKIs) such as imatinib, among others
US$ 29.25
US$ 24.17
US$ 24.43
